Boston Scientific Corporation (NYSE: BSX) has announced that in a move to expand significantly its portfolio of leading solutions for peripheral interventions, it has entered into a definitive agreement to acquire the Interventional Division of Bayer AG for $415 million in cash, including fees for transitional services.  As noted in the company press release, below, the company expects to close the transaction in the second half of 2014, subject to customary closing conditions.  Latham & Watkins LLP advised Boston Scientific on the transaction with a corporate team led by Boston partners Johan (Hans) Brigham and Julie Scallen with associates Keith Grannis and Michael Bookman.